Zomig Nasal Spray
"March 11, 2014 - The U.S. Food and Drug Administration allowed marketing of the first device as a preventative treatment for migraine headaches. This is also the first transcutaneous electrical nerve stimulation (TENS) device specifically "...
Zomig Nasal Spray
There is no experience with acute overdose. Clinical study subjects receiving single 50 mg oral doses of zolmitriptan commonly experienced sedation.
The elimination half-life of ZOMIG is 3 hours [see CLINICAL PHARMACOLOGY] and therefore monitoring of patients after overdose with ZOMIG should continue for at least 15 hours or while symptoms or signs persist.
There is no specific antidote to zolmitriptan. In cases of severe intoxication, intensive care procedures are recommended, including establishing and maintaining a patent airway, ensuring adequate oxygenation and ventilation, and monitoring and support of the cardiovascular system.
ZOMIG is contraindicated in patients with:
- Ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), other significant underlying cardiovascular disease, or coronary artery vasospasm including Prinzmetal's angina [see WARNINGS AND PRECAUTIONS]
- Wolff-Parkinson-White Syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see WARNINGS AND PRECAUTIONS]
- History of stroke, transient ischemic attack (TIA) or history of hemiplegic or basilar migraine because these patients are at higher risk of stroke [see WARNINGS AND PRECAUTIONS]
- Peripheral vascular disease (PVD) [see WARNINGS AND PRECAUTIONS]
- Ischemic bowel disease [see WARNINGS AND PRECAUTIONS]
- Uncontrolled hypertension [see WARNINGS AND PRECAUTIONS]
- Recent use (i.e., within 24 hours) of another 5-HT1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see DRUG INTERACTIONS]
- Concurrent administration of an MAO-A inhibitor or recent discontinuation of a MAO-A inhibitor (that is within 2 weeks) [see DRUG INTERACTIONS and CLINICAL PHARMACOLOGY]
- Known hypersensitivity to ZOMIG (angioedema and anaphylaxis seen) [see ADVERSE REACTIONS]
Last reviewed on RxList: 9/30/2013
This monograph has been modified to include the generic and brand name in many instances.
Additional Zomig Nasal Spray Information
Zomig Nasal Spray - User Reviews
Zomig Nasal Spray User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find the secrets to longer life.